GERMANY: First clinical trial of COVID-19 vaccine approved
The German biotech companies BioNTech SE and Pfizer Inc. have announced that the German regulatory authority, the Paul-Ehrlich-Institut, has approved the Phase 1/2 clinical trial for BioNTech’s BNT162 vaccine program to prevent COVID-19 infection. The trial is the first clinical trial of a COVID-19 vaccine candidate to start in Germany, and is part of a global development programme. The company...